Target Price | $1.02 |
Price | $0.33 |
Potential |
208.16%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Cyclacel Pharmaceuticals, Inc. 2026 .
The average Cyclacel Pharmaceuticals, Inc. target price is $1.02.
This is
208.16%
register free of charge
$1.05
217.22%
register free of charge
$1.01
205.14%
register free of charge
|
|
A rating was issued by 6 analysts: 0 Analysts recommend Cyclacel Pharmaceuticals, Inc. to buy, 3 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Cyclacel Pharmaceuticals, Inc. stock has an average upside potential 2026 of
208.16%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 0.04 | 0.10 |
90.48% | 155.00% | |
Net Margin | -28,025.00% | -15,292.80% |
417.16% | 45.43% |
3 Analysts have issued a sales forecast Cyclacel Pharmaceuticals, Inc. 2025 . The average Cyclacel Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Cyclacel Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Cyclacel Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -33.50 | -1.20 |
92.17% | 96.42% | |
P/E | negative | |
EV/Sales | 43.24 |
3 Analysts have issued a Cyclacel Pharmaceuticals, Inc. forecast for earnings per share. The average Cyclacel Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Cyclacel Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.